Patient demographic and baseline characteristics
| Parameter . | Patients (N = 25) . |
|---|---|
| Sex, n (%) | |
| Female | 10 (40) |
| Male | 15 (60) |
| Age, y* | |
| Mean (SD) | 59 (8) |
| Median | 59 |
| Minimum, maximum | 45, 72 |
| Race, n (%) | |
| Black or African American | 5 (20) |
| White | 19 (76) |
| Multiracial | 1 (4) |
| HLA status, n (%) | |
| HLA-A2+ | 25 (100) |
| NY-ESO-1 status, n (%) | |
| NY-ESO-1+ | 14 (56) |
| NY-ESO-1− | 11 (44) |
| LAGE-1 status, n (%) | |
| LAGE-1+† | 25 (100) |
| ECOG performance status, n (%) | |
| 0 | 7 (28) |
| 1 | 16 (64) |
| 2 | 2 (8) |
| Previous therapies, n (%)‡ | |
| 1 | 5 (20) |
| 2 | 6 (24) |
| 3 | 4 (16) |
| >4 | 10 (40) |
| Cytogenetic abnormalities, n (%) | |
| ≥1 | 12 (48) |
| Deletion (13q) | 8 (32) |
| Deletion (17p) | 1 (5) |
| Hypodiploid | 0 (0) |
| Transduced cell dose, n (%) | |
| <1 × 109 | 3 (12) |
| 1-5 × 109 | 21 (84) |
| ≥5 × 109 | 1 (4) |
| Median (range) | 3.1 × 109 (0.5-5.05 × 109) |
| Parameter . | Patients (N = 25) . |
|---|---|
| Sex, n (%) | |
| Female | 10 (40) |
| Male | 15 (60) |
| Age, y* | |
| Mean (SD) | 59 (8) |
| Median | 59 |
| Minimum, maximum | 45, 72 |
| Race, n (%) | |
| Black or African American | 5 (20) |
| White | 19 (76) |
| Multiracial | 1 (4) |
| HLA status, n (%) | |
| HLA-A2+ | 25 (100) |
| NY-ESO-1 status, n (%) | |
| NY-ESO-1+ | 14 (56) |
| NY-ESO-1− | 11 (44) |
| LAGE-1 status, n (%) | |
| LAGE-1+† | 25 (100) |
| ECOG performance status, n (%) | |
| 0 | 7 (28) |
| 1 | 16 (64) |
| 2 | 2 (8) |
| Previous therapies, n (%)‡ | |
| 1 | 5 (20) |
| 2 | 6 (24) |
| 3 | 4 (16) |
| >4 | 10 (40) |
| Cytogenetic abnormalities, n (%) | |
| ≥1 | 12 (48) |
| Deletion (13q) | 8 (32) |
| Deletion (17p) | 1 (5) |
| Hypodiploid | 0 (0) |
| Transduced cell dose, n (%) | |
| <1 × 109 | 3 (12) |
| 1-5 × 109 | 21 (84) |
| ≥5 × 109 | 1 (4) |
| Median (range) | 3.1 × 109 (0.5-5.05 × 109) |
ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.
Age at informed consent/screening.
One patient tested positive for LAGE-1 per the laboratory report at screening but was erroneously recorded as LAGE-1 negative in the database, and this was not corrected prior to database lock.
Four patients had received a prior autologous stem cell transplant.